Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study

• Published in: Journal of the European Academy of Dermatology and Venereology Vol. 27; no. 3; pp. e376 - e383
• Main Authors: Papp, K.A., Kaufmann, R., Thaçi, D., Hu, C., Sutherland, D., Rohane, P.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.03.2013
• Subjects: Alcoholism; Anti-Inflammatory Agents, Non-Steroidal - adverse effects; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use; Anxiety; BID protein; Diarrhea; Double-Blind Method; Drug abuse; Headache; Humans; Inflammation; Knee; Nausea; Opportunist infection; phosphodiesterase IV; Placebos; Plaques; Psoriasis; Psoriasis - drug therapy; Rehabilitation; Rhinopharyngitis; Severity of Illness Index; Surface area; Surgery; Thalidomide - adverse effects; Thalidomide - analogs & derivatives; Thalidomide - therapeutic use

Background  Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works intracellularly to modulate pro‐inflammatory and anti‐inflammatory mediator production. Objective  Assess apremilast efficacy and safety in moderate to severe plaque psoriasis. Methods  Phase II, 12‐week, multi...